Table 2.
Our study: n (%) | MPACT trial: n (%) | |
---|---|---|
Survival data | ||
Progression-free survival, median (months) | 4.8 | 5.5 |
Overall survival, median (months) | 9.1 | 8.5 |
Grade 3 or 4 toxicities | ||
Growth-factor support | 48 (66%) | 110 (26%) |
Anemia | 7 (10%) | 53 (13%) |
Neutropenia | 2 (2%) | 153 (38%) |
Neutropenic fever | 0 (0%) | 14 (3%) |
Thrombocytopenia | 3 (3%) | 52 (13%) |
Neurotoxicity | 5 (5%) | 70 (17%) |
Dose reduction in patients | ||
Nab-paclitaxel | 3 (3%) | 41% |
Gemcitabine | 7 (10%) | 47% |